Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association Between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract?

S Qadwai
T Rehman
Jonathan Barsa
New York Medical College
Z Solangi
Edward Lebovics
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Neoplasms Commons, Oncology Commons, and the Virus Diseases Commons

Recommended Citation
Qadwai, S., Rehman, T., Barsa, J., Solangi, Z., & Lebovics, E. (2017). Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association Between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract?. Gastroenterology Research and Practice, 2017, Art. ID 8349150. https://doi.org/10.1155/2017/8349150

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact touro.scholar@touro.edu.
Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract?

Saad Qadwai,1 Tayyaba Rehman,2 Jonathan Barsa,1 Zeeshan Solangi,1 and Edward Lebovics1

1New York Medical College and Westchester Medical Center, 100 Woods Road, Valhalla, NY 10595, USA
2Bristol-Myers Squibb, 5 Research Pkwy, Wallingford, CT 06492, USA

Correspondence should be addressed to Saad Qadwai; s_qadwai@hotmail.com

Received 30 December 2016; Revised 28 March 2017; Accepted 3 April 2017; Published 3 May 2017

Hepatitis C virus (HCV) is known for its oncogenic potential and has been found to be associated with hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma. It has also been postulated that HCV may play a role in the development of extrahepatic solid tumors of other organs of the body since it has been isolated from the blood vessel wall, kidney, and oral mucosa. In this article, we have reviewed epidemiological studies that have been done to look into the relationship of HCV with nonliver solid cancers of the pancreas, thyroid, renal, oral cavity, breast, and lung and nonpancreatic gastrointestinal cancers. Based on this review, HCV might be associated with an increased risk of renal cell and lung cancers.

1. Introduction

Approximately 180 million people worldwide are infected by hepatitis C virus (HCV) including almost three million people in the US [1, 2]. HCV virus is known for its oncogenic potential and has been found to be associated with hepatocellular carcinoma (HCC) [3] and non-Hodgkin lymphoma [4]. It has also been postulated that HCV may play a role in the development of extrahepatic solid tumors of other organs of the body since it has been isolated from the blood vessel wall, kidney, and oral mucosa [5–7]. The possible oncogenic effects of HCV can be through various molecular, genetic, and environmental mechanisms. These mechanisms include complement-mediated tissue injury, inhibition of lymphocyte-mediated apoptosis, and mutation of somatic genes like proto-oncogenes or tumor suppressor genes [5, 8–21]. In this article, we have reviewed epidemiological studies that have evaluated the relationship of HCV with nonliver solid tumors.

2. Method

We conducted a MEDLINE search of published articles to identify epidemiologic studies on the potential association between HCV infection and solid malignancies other than HCC. We focused on the following malignancies: (1) pancreatic cancer (PAC), (2) thyroid cancer (TC), (3) renal cancer (RC), (4) oral cancer (OC), (5) breast cancer (BC), (6) lung cancer (LC), (7) esophageal cancer (EC), (8) stomach cancer (SC), and (9) colorectal cancer (CRC).

The inclusion criteria of our analysis were as follows:

(1) Case-control and cohort study designs focusing on adult population
(2) Full-text publications and peer-reviewed articles in the English language
(3) Studies that described diagnostic testing for the HCV infections in the participants, for example, enzyme-
linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) for the presence of HCV RNA.

The exclusion criteria of our analysis were case reports and case series.

The MEDLINE search of articles on the association of hepatitis C and nonliver cancers produced the following citations: (1) PAC: 144; (2) TC: 65; (3) RC: 239; (4) OC: 179; (5) BC: 111; (6) LC: 185; (7) EC: 91; (8) SC: 93; and (9) CRC: 118. We screened the potentially relevant studies and, in accordance with predefined criteria, we identified and considered in our systematic review the following number of studies on the association of hepatitis C and nonliver cancers: (1) PAC: 3 case-control studies and 7 cohort studies; (2) TC: 5 case-control studies and 7 cohort studies; (3) RC: 3 case-control studies and 4 cohort studies; (4) OC: 2 case-control studies and 4 cohort studies; (5) BC: 2 case-control studies and 5 cohort studies; (6) LC: 2 case-control studies and 4 cohort studies; and (7) esophagus/stomach/colon/rectal: 2 case-control studies and 5 cohort studies.

3. Results

3.1. Pancreatic Cancers. In Woo et al., anti-HCV seropositivity was found to be associated with increased risk of developing PAC [22]. In contrary, Chang et al. and Hassan et al. did not find HCV infection to be associated with an increased risk of PAC [23, 24] (Table 1).

In a population-based cohort study, Abe et al. did not find HCV to be associated with increased risk of PAC as compared to individuals without a positive infection marker in a 324,394 person-years follow-up [25]. Huang et al. conducted a nationwide cohort study in Sweden using a National Surveillance Database from 1990 to 2006 and followed to the end of 2008 [26]. The PAC risk in the study population was compared to the general population [26]. In a total of 340,819 person-years in the HCV cohort, 34 PACs were identified [26]. It was noted that HCV slightly increases the risk of pancreatic cancer as compared to general population [26]. El-Serag et al. conducted a cohort study including 146,394 HCV-infected and 572,293 HCV-uninfected patients who received care at Veterans Affairs health care facilities between 1996 and 2004 [27]. In the 1.37 million person-years of follow-up, HCV-associated risk of PAC was slightly elevated, which was attenuated after adjusting for alcohol use, pancreatitis, cholelithiasis or choledocholithiasis, HBV, or primary sclerosing cholangitis [27]. An increased risk of PAC was also noticed among HCV-infected patients in Omland et al. [35]. However, Amin et al. did not show an increased incidence of PAC in HCV-diagnosed patients [28] (Table 2).

3.2. Thyroid Cancers. Five case-control studies completed in Italy by Antonelli et al. and Montella et al. have shown consistently increased prevalence and risk of TC among patients diagnosed with HCV infection (Table 3) [29–33]. Antonelli et al. noted six cases of TC in 308 HCV (+) patients, while no TC patient was noted in 616 healthy subjects from iodine-deficient areas (P = 0.001) and only one TC was noted in 616 healthy subjects from iodine-sufficient areas (P = 0.003) [29]. Montella et al. showed a statistically significant association between HCV and papillary TC [30]. In another case control study, Antonelli et al. compared the prevalence of TC among HCV-related mixed cryoglobulinemic patients to a five-sex-matched control group of subjects aged > 50 years and who had undergone thyroid ultrasound. They noticed two cases of papillary TC in patients with HCV-related mixed cryoglobulinemia (2/94), while no case was observed among controls (0/582) (P = 0.001) [31]. In another case-control study, Montella et al. found an association between HCV and TC in overall population and subjects ≥ 50 years [32]. In another study, Antonelli et al. found 3 incidences of TC on fine-needle aspiration (FNA) biopsy of HCV (+) cases while no TC was noted in HCV (−) control group (P = 0.004) [33] (Table 3). In contrary to the case control studies, none of the cohort studies done in the United States, Australia, Denmark, Sweden, and Taiwan showed an association between HCV and TC [4, 28, 34–37] (Table 4).

3.3. Renal Cancers. Gonzalez et al. screened for anti-HCV antibodies and HCV RNA in patients with suspected RC and colon cancer (controls) [38]. They found increased detection of anti-HCV and HCV RNA in RC cases as compared to colon cancer controls (Table 5) [38]. Malaguarnera et al. compared the prevalence of HCV infection in cancer patients to volunteers (controls) [39]. Increased prevalence of anti-HCV was found in patients with RC cases as compared to control group [41]. However, Budakoglu et al. found no significant increase in HCV positivity in RC patients compared to healthy control group [40] (Table 5).

In a cohort study, Gordon et al. HCV tested cases between 1997 and 2006 were followed for the development
| Author          | Country | Study period | Total number of subjects | PC (n)/HCV (+) cases (n) | PC (n)/HCV (−) cases (n) | OC   | EC   | Person-years | Risk (95% CI)  |
|-----------------|---------|--------------|--------------------------|--------------------------|--------------------------|------|------|--------------|----------------|
| Abe et al. [25] | Japan   | 16 years     | 20,360                   | NA/1129                  | NA/19,231                | NA   | NA   | 324,394      | HR* 0.7 (0.3–1.7) |
| Allison et al. [34] | USA     | 2006–2010   | 2,143,369                | 19/12,126                | NA/2,131,243             | NA   | NA   | 39,984       | SRR 2.5 (1.7–3.2) |
| Huang et al. [26] | Sweden  | 1990–2006   | 50,953                   | 34/39,442                | 120/197,208              | 34   | 16.5 | 360,154      | SIR** 2.1 (1.4–2.9) |
| Omland et al. [35] | Denmark | 1994–2003   | 4204                     | NA                       | 4/4204                   | NA   | 1    | 15,980       | SIR 3.9 (1.1–10.1) |
| El-Serag et al. [27] | USA     | 1996–2004   | 718,687                  | NA/146,394               | NA/572,293               | NA   | NA   | 280,676***   | HR***** 1.2 (1.0–1.5) |
| Amin et al. [28] | Australia | 1990–2002  | 117,547                  | 17/75,834                | NA                       | 17   | NA   | 356,775      | SIR 1.4 (0.8–2.2) |

CI: confidence interval; OC: observed cases; EC: expected cases; SRR: standardized rate ratios; SIR: standardized incidence ratios; OST: opioid substitution therapy. *HR adjusted for age, sex, study area, diabetes, BMI, and smoking. **SIR WITH lag period after 6 months of HCV notification. ***Person-years in HCV infected cohort. ****Person-years in HCV-uninfected cohort. *****HR adjusted for age, sex, baseline visit date, type of visit (inpatient or outpatient) for the baseline visit, and a preceding visit, previous VA use, and era of military service.
Table 3: Case-control studies for association of chronic HCV infection with thyroid cancer (TC).

| Author            | Country | Study design                                      | Sample size (n) | HCV (+) cases (n)/total cases (n) | HCV (+) controls (n)/total controls (n) | Factors adjusted | OR (95% CI)        | P value |
|-------------------|---------|---------------------------------------------------|-----------------|-----------------------------------|-----------------------------------------|------------------|-------------------|---------|
| Antonelli et al. [29] | Italy   | Controla                                         | 1540            | 6/308                             | 0/616a                                  | N/A              | N/A               | 0.001a  |
| Montella et al. [30] | Italy   | HCV diagnosis—ELISA and PCR                       | 34/372          | 16/130                            | 18/242                                  | N/A              | 3.3 (1.5–7.4)     | 0.003   |
| Antonelli et al. [31] | Italy   | TC in HCV related MC                              | 564             | 2/94                              | 0/582                                   | N/A              | N/A               | 0.001   |
| Montella et al. [32] | Italy   | HCV prevalence in different cancers versus controls | 356             | 16/130                            | 17/226                                  | Age, sex         | (a) Overall population 2.8 (1.2–6.3) | (a) 0.01 |
|                    |         | 130 TC cases                                      |                 |                                   |                                         |                  | (b) ≥50 years 3.1 (1.2–8.0) | (b) 0.01 |
| Antonelli et al. [33] | Italy   | FNA of PTN                                       | 974             | 3/139                             | 0/835                                   | N/A              | N/A               | 0.004   |

CI: confidence interval; a: control—iodine deficient area; b: control—iodine sufficient area; ELISA: enzyme-linked immunosorbent assay; PCR: polymerase chain reaction; MC: mixed cryoglobulinemia patients; FNA: fine-needle aspiration; PTN: palpable thyroid nodules; NA: not available.
Table 4: Cohort studies for association of chronic HCV infection with thyroid cancer (TC).

| Author et al. [37] | Country | Study period | Total number of subjects | TC (n)/HCV (+) cases (n) | TC (n)/HCV (-) cases (n) | OE | EC | Person-years | Risk (95% CI) |
|-------------------|---------|--------------|--------------------------|--------------------------|--------------------------|----|----|--------------|---------------|
| Sweden | 1990–2000 | 27,150 | NA/27,150 | NA | 5 | NA | 122,272 | SIR | 1.5 (0.5–3.6) |
| USA | 1997–2004 | 718,687 | NA/146,394 | NA/572,293 | NA | NA | HCV (+) 280,676 | HCV (-) 1,095,911 | HR* | 0.7 (0.5–0.9) |
| USA | 2006–2010 | 2,143,369 | 6/12,126 | NA/2,131,243 | NA | NA | 39.984 | SRR | 1.1 (0.6–1.6) |
| Denmark | 1994–2003 | 4204 | 1/4204 | NA | 1 | 0.5 | 15,980 | SIR | 2.1 (0.1–12.0) |
| Australia | 1990–2002 | 117,547 | 9/75,834 | NA | 9 | NA | 356,775 | SIR | 0.3 (0.2–0.7) |
| Australia | 1993–2007 | 29,613 | 5/14,892 | NA | 5 | 6.8 | 213,008 | SIR | 0.7 (0.2–1.7) |

OC: observed cases; EC: expected cases; CI: confidence interval; SIR: standardized incidence ratio; HR: hazard ratio; *HR adjusted for age, sex, race, baseline visit date, type of visit (inpatient or outpatient) for the baseline visit and a preceding visit, previous VA use, and era of military service; NA: not available.
of RC until April 2008. The adjusted hazard ratio (HR) for age, African-American race, male gender, and chronic kidney disease (CKD) was 1.77 (95% CI 1.1–2.9, P 0.03) [41]. In contrary, another nationwide registry-based cohort study conducted in Sweden on individuals with chronic HCV infection diagnosed between 1990 and 2006 with a mean follow-up time of 9.3 years did not show increased standardized incidence rate (SIR) for RC in this population. Also, SIR was not found to be significantly increased in Omland et al. and Amin et al. [28, 35] (Table 6).

3.4. Oral Cancers. Nagao et al. demonstrated both significantly increased detection of anti-HCV antibodies and HCV RNA in patients with OC as compared to control group. Also, significantly decreased prevalence of anti-HCV antibodies was noticed in patients with SC as compared to OC patients [43]. Takata et al. found increased prevalence of HCV antibody in patients with OC as compared to patients with impacted teeth but the association reversed after age adjustment [44] (Table 7).

In a prospective study done by Su et al., incidence of OCs was 2.28-fold higher (6.15 versus 2.69 per 10,000 person-years) among patients with HCV than those in the nonviral hepatitis group (HR 1.9, 95% CI 1.2–3.0) [45]. The positive association was highest among individuals in the 40–49 year age group (HR 2.57, 95% CI 1.2–5.4) [45]. However, Amin et al. did not show an increased association of HCV with cancers of the mouth, tongue, and tonsil [28]. However, Swart et al. showed an increased incidence of cancers of the mouth in patients found to be HCV-positive [36] (Table 8).

3.5. Breast Cancers. Su et al. conducted a nationwide population-based case-control study in Taiwan [46] in which 1958 patients with newly diagnosed BC were identified from the National Health Insurance Research Database (NHIRD) between 2000 and 2008 [46]. A randomly selected sample of age-matched cohort of 7832 subjects without cancer was selected for comparison [46]. Three percent of BC subjects had HCV and 2.3% non-BC subjects had HCV [46]. No significant association between HCV infection and BC was found (adjusted OR 1.2, 95% CI 0.9–1.7) after adjusting for area, occupation, urbanization, and income [46]; however, age < 50 years was found to be associated with a 2-fold greater risk of developing BC (OR 2.0, 95% CI 1.2–3.3) among HCV-infected persons [46]. A single-center case control study was performed in France by Larrey et al. in which females aged ≥ 20 years with present and/or past history of chronic HCV infection based on detection of serum anti-HCV antibodies, HCV RNA by PCR, and liver biopsy consulting in an outpatient liver unit for 1 year [47] were included. The control group included female patients with other chronic liver diseases: chronic hepatitis B, alcoholic liver disease, autoimmune hepatitis, hemochromatosis, non-alcoholic liver disease, and chronic cholangitis. The results of this study noted a higher prevalence of BC in the HCV group (17/294, 6%, 95% CI 3.1–8.4), but there was no significant statistical difference with the control group (5/107, 5%, 95% CI 0.7–8.7) [47]. Furthermore, no significant difference in BC was found among HCV and control group for females younger than 40 years (0/28 versus 0/12), between 41 and 60 years (5/146, 3.4%, 95% CI 0.5–6.4 versus 1/55, 2%, 95% CI 0–5.3), and older than 60 (12/120, 10%, 95% CI 4.6–15.4 versus 4/40, 10%, 95% CI 0.7–19.3) [47].

HCV was not found to be associated with an increased incidence of BC in cohort studies conducted by Allison et al. (SRR 0.7, 95% CI 0.6–0.8), Omland et al. (SIR 0.25,
3.6. Lung Cancers. In a Turkish retrospective study conducted by Uzun et al., anti-HCV antibodies were tested in 45 patients with LC, 80 patients with benign lung disease, and 135 healthy controls [48]. Detection of anti–HCV abs were significantly higher (P < 0.05) among LC patients (3/45) as compared to patients with benign lung disease (0/80) and the healthy controls (1/135) [48]. In another case control study conducted by Malaguarnera et al., increased prevalence of anti-HCV was found in patients with LC (8/22 versus 30/300) as compared to those in the control group (36% versus 10%, P < 0.05) [39].

In Allison et al., HCV infection was found to be associated with a slightly increased incidence of LC (SRR 1.6, 95% CI 1.3–1.9) [34]. Similarly, in Swart et al., increased incidence of cancer of the trachea, bronchus, and lung were noted (SIR 4.6, 95% CI 2.8–7.1) among subjects infected with HCV [36]. However, in Omland et al., HCV was not found to be associated with increased incidence of lung cancer (SIR 1.95, 95% CI 0.93–3.58) [35]. Similarly, in Amin et al., HCV was not found to be associated with the increased incidence of cancer of the larynx (SIR 1.0, 95% CI 0.4–2.3) and trachea (SIR 1.2, 95% CI 0.9–1.5) [28].

3.7. Gastrointestinal (GI) Cancers. Increased risk of EC among HCV-infected population was not observed in the studies done by Amin et al. (SIR 0.5, 95% CI 0.2–1.4) [28], Allison et al. (SRR 2.1, 95% CI 0.9–3.2) [34], and Omland et al. (SIR 1.6, 95% CI 0.04–9.2) [35]. Also, no statistically significant association was found between HCV and SC in Amin et al. (SIR 1.4, 95% CI 0.9–2.1) [28] and Allison et al. (SRR 1.1, 95% CI 0.5–1.6) [34]. A case-control study by Malaguarnera et al. found an increased prevalence of anti-HCV antibodies in patients with colorectal cancer as compared to controls (8/22 (36%) versus 30/300 (10%), P < 0.05) [39].

In Allison et al., an increased incidence of rectal cancer was also found in patients with chronic HCV infection (SRR 2.1, 95% CI 1.3–2.8) [34], but colon cancer incidence rate did not increase in chronic HCV-infected patients (SRR 0.4, 95% CI 0.3–0.6) [34]. Colon cancer incidence rate was also not increase in HCV-infected patients in studies by Amin et al. (SIR 0.6, 95% CI 0.5–0.9) [28] and Omland et al. (SIR 1.0, 95% CI 0.2–2.9) [35]. Similarly, no increased incidence of rectal cancer was observed in HCV patients in Amin et al. (SIR 0.3, 95% CI 0.2–0.6) [28] and Omland et al. (SIR 1.8, 95% CI 0.4–5.4) [35]. Furthermore, no increased incidence of CRC was observed in patients with HCV notification (SIR 0.9, 95% CI 0.4–1.8) in Swart et al. [36].

4. Discussion

HCV has a hepatotropic potential and is well known for causing hepatocellular carcinoma. Since both liver and pancreas share common endodermal origin, it is postulated that HCV may replicate in pancreatic cells as well [49, 50]. Thus, HCV may play a role in the development of PAC. However, most of the epidemiological studies have not shown an association between the HCV and PAC. Among these, two case-control studies and one cohort study were conducted in Asian population [22, 23, 25]. Only one case-control study done in Korea showed an increased risk of PAC in HCV-positive subjects [22]. On the other hand, focused cohort studies which have not utilized administrative data have not shown a positive association between HCV and PAC [25, 27]. Based on current information, increased PAC screening among HCV-infected patients is not clearly indicated.

Antonelli et al. and Montella et al. collaborated to conduct five case-control studies on the association of HCV and TC in Italy. They have consistently shown an increased association between HCV and TC [29–33]. Although they did not adjust for some of the TC risk factors in their analyses such as history of radiation exposure, they were still able to show increased risk of TC among HCV (+) population as compared to controls from iodine-deficient areas [29] and among population ≥50 years [32]. However, no cohort study has been done in Italy to confirm this association between HCV and TC. None of the cohort study done in other parts of the world has shown any significant relationship between HCV and TC [4, 28, 34, 35, 37]. It could be possible that a high prevalence of HCV in certain parts of the world may result in an increased risk of developing TC which could be further explained by genetic and environmental factors. Until now, the data does not clearly support an increase in TC screening among HCV-infected patients.
Table 8: Cohort studies for association of chronic HCV infection with oral cancer (OC).

| Author          | Country     | Study period | Total number of subjects | OC (n)/HCV (+) cases (n) | OC (n)/HCV (−) cases (n) | OC | EC | Person-years | Risk (95% CI) |
|-----------------|-------------|--------------|--------------------------|--------------------------|---------------------------|----|----|--------------|---------------|
| Su et al. [45]  | Taiwan      | 1996–2008    | 21/5311                  | 147/84796                | NA                        | NA | NA | 78,803       | HR 1.9 (1.2–3.0) |
| Amin et al. [28]| Australia   | 1990–2002    | 117,547                  | 19/75,834                | NA                        | NA | NA | 356,775      | Mouth – 1.5 (0.7–3.2) |
|                 |             |              |                          |                          |                           |     |     |              | SIR            |
|                 |             |              |                          |                          |                           |     |     |              | Tongue – 1.1 (0.5–2.4) |
|                 |             |              |                          |                          |                           |     |     |              | Tonsil – 2.1 (1.0–4.8) |
| Allison et al. [34]| Australia  | 1993–2007    | 29,613                   | Mouth 3/14,892 Lip 3/14,892 | NA                        | Mouth 3 | Mouth 0.58 Lip 2.19 | 213,008 | Mouth – 5.1 (1.0–15.0) |
|                 |             |              |                          |                          |                           |     |     |              | SIR            |
|                 |             |              |                          |                          |                           |     |     |              | Lip – 1.3 (0.28–4.00) |

OC: observed cases; EC: expected cases; CI: confidence interval; SIR: standardized incidence rate; SMR: standardized mortality rate; NA: not available.
protein ligase-related mechanism [51]. Among three case-control studies, two studies, that is, Gonzalez et al. and Malaguarnera et al., have shown an increased risk of RCC in HCV (+) population [38, 39]. These studies confirmed the HCV status of their subjects by testing for HCV RNA [38, 39]. Moreover, Gonzalez et al. used CRC patients as controls in their study who are expected to have a higher risk of acquiring HCV infection due to frequent hospitalizations and medical procedures as compared to the general population [38]. The result of the study still showed statistically increased prevalence of anti-HCV antibodies and HCV RNA in the RCC patients as compared to the CRC patients [38, 39]. Gordon et al. conducted a follow-up cohort study to the findings of Gonzalez et al. and confirmed that HCV increases the risk of RCC [38, 41]. Based on current data, HCV could be associated with increased risk of RCC. Clinicians should consider screening newly diagnosed RC cases for HCV virus. Also, low threshold should be maintained for screening RC in population positive for HCV in the US.

Few epidemiological studies have been done and most were limited to Asia, to determine an association between HCV and OC. The two case-control studies done in Japan have shown conflicting results [43, 44]. Nagao et al. showed increased association between HCV and OC [43]. On the other hand, Takata et al. also showed an increased risk but it turned into a protective effect after adjusting for age [44]. A large cohort study conducted by Su et al. on Chinese population showed an increased risk of OC in HCV-infected population as compared to HCV-negative population [45]. However, cohort studies done outside of Asian population has not shown an association. Until now, no definitive conclusions can be obtained from the data on the association of HCV and OC and more studies are needed utilizing information on the risk factors of OC to be adjusted in the data analyses for making more definite conclusions.

Epidemiologic studies on the relationship of HCV and BC have consistently failed to show an association [28, 34–36, 46, 47]. Only Su et al. noticed an increased risk in women aged < 50 years [46]. Thus, recent epidemiologic data on the association of HCV and BC do not confer a causative relationship. Therefore, increased screening of BC in chronic HCV infection is not warranted.

Two case-control studies done in Turkey and Italy, by Malaguarnera et al. and Uzun et al., on the association of HCV and LC have observed that HCV increases the risk of lung cancer [39, 48]. Until now, no cohort study has specifically looked into the association of HCV and LC. Although the four cohort studies have shown an increased risk of LC in HCV-infected population [28, 34–36], two of them did not find the risk statistically significant [28, 35]. Currently, limited epidemiological studies have suggested some association between HCV and LC. Clinicians may consider keeping a low threshold for screening chronic HCV infection for LC until further more focused prospective studies evaluate the relationship between HCV and LC in more detail.

The data on the association of HCV and nonpancreatic GI cancers is very limited and consist mainly of a case control study done in Italy [39] and a few cohort studies based on administrative datasets [28, 34–36]. Malaguarnera et al. showed increased prevalence of anti-HCV antibodies among CRC as compared to controls [39]. Also, Allison et al. found increased incidence of rectal cancer in HCV-infected population [34]. None of the other cohort studies were able to confirm these associations. None of the cohort studies found an association between HCV and EC or SC [28, 34, 35]. Thus, it can be concluded that the current data on the association of HCV and nonpancreatic GI cancers is very limited and does not clearly indicate if there is an association.

Most of available data on the association of HCV and nonhepatic solid cancers have been obtained from cohort studies. The large size and lengthy follow-up of these studies provides the adequate statistical power to determine the cancer risk in the study population. However, lack of consistency has been found across the epidemiological studies on the association of HCV and nonhepatic solid cancers which could be explained by the limitations associated with them. These limitations include small sample size of some case-control studies, errors in diagnosis in administrative dataset, representation of only a part of the general population in the national cancer registry, and missing data. This may result in underestimation or overestimation of the risk and makes it difficult to interpret the results of these studies. For example, two case-control studies done in Turkey and Italy, by Malaguarnera et al. and Uzun et al., were limited by a small sample size [48] and not being able to adjust for risk factors of LC like smoking, radiation exposure, occupation, and family history of LC [39, 48]. Similarly, Su et al. lacked information on several variables associated with BC, for example, body mass index, fertility, and use of oral contraceptive to adjust for confounding in their analyses [46]. Woo et al. utilized paired matching to match their controls with cases for age, sex, and date of admission or visit but did not use conditional logistic regression for analyzing the data as indicated when controls are pair-matched to cases [22]. Also, there were too much missing data (66%) in this study which may have contributed to bias to their analyses [22]. Budakoglu et al. did not confirm the anti-HCV antibody-positive status of the subjects with HCV RNA which could have resulted in a bias in their analysis since anti-HCV antibodies can be falsely positive due to old infection or secondary to cross-reactivation with other infections [40]. Hofmann et al. excluded 623 HCV-infected subjects from the analyses due to incomplete information [42]. It is not known if the characteristics of the subjects excluded from the analyses were similar to those who were included and thus may have resulted in a bias [42]. A large cohort study conducted by Su et al. showed an increased risk of OC in HCV-infected population as compared to HCV-negative population [45]. However, this study also lacked information on some of the risk factors of oral cancer like smoking, alcohol consumption, and betel squid chewing to adjust them in their analyses [45]. Although Malaguarnera et al. observed an increased prevalence of HCV RNA in LC patients as compared to controls (26% versus 6.6%), they did not confirm this by using statistical analyses to look for significance [39]. Moreover, no study has looked into the role of different HCV genotypes in causing a specific type of nonhepatic solid cancer.
The data on the association between HCV and many nonhepatic solid cancers are still in the initial stages and are not very conclusive. More epidemiological studies are needed in different regions of the world to confirm these associations observed in this review.

Disclosure

The authors hereby certify that they have no involvement in the subject matter or materials discussed in this manuscript.

Conflicts of Interest

There is no declared conflict of interest.

References

[1] E. Gower, C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, “Global epidemiology and genotype distribution of the hepatitis C virus infection,” *Journal of Hepatology*, vol. 61, no. 1, Supplement 1, pp. S45–S57, 2014.

[2] M. M. Denniston, R. B. Jiles, J. Drobeniuc et al., “Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010,” *Annals of Internal Medicine*, vol. 160, no. 5, pp. 393–300, 2014.

[3] Z. M. Younossi, F. Kanwal, S. Saab et al., “The impact of hepatitis C burden: an evidence-based approach,” *Alimentary Pharmacology & Therapeutics*, vol. 39, no. 5, pp. 518–531, 2014.

[4] T. P. Giordano, L. Henderson, O. Landgren et al., “Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus,” *Journal of the American Medical Association*, vol. 297, no. 18, pp. 2010–2017, 2007.

[5] H. M. Ko, J. C. Hernandez-Prera, H. Zhu et al., “Morphologic features of extrahepatic manifestations of hepatitis C virus infection,” *Clinical & Developmental Immunology*, vol. 2012, Article ID 740138, p. 9, 2012.

[6] D. Sansonno, G. Lauletta, M. Montrone, G. Grandaliano, F. P. Schena, and F. Dammacco, “Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection,” *Clinical and Experimental Immunology*, vol. 140, no. 3, pp. 498–506, 2005.

[7] M. Carrozzi, R. Quadri, P. Latorre et al., “Molecular evidence that the hepatitis C virus replicates in the oral mucosa,” *Journal of Hepatology*, vol. 37, no. 3, pp. 364–368, 2002.

[8] F. V. Chisari, “Cytotoxics T cell and viral hepatitis,” *The Journal of Clinical Investigation*, vol. 99, no. 7, pp. 1472–1477, 1997.

[9] J. Lamontagne, M. Pinkerton, T. M. Block, and X. Lu, “Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine-protease dependent apoptosis,” *Journal of Virology*, vol. 84, no. 2, pp. 907–917, 2010.

[10] A. Lukkonen, S. Lintula, K. von Boguslawski et al., “Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients,” *International Journal of Cancer*, vol. 83, no. 4, pp. 486–490, 1999.

[11] K. Machida, K. T. Cheng, V. M. Sung et al., “Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and prothrombocytopenic,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 12, pp. 4262–4267, 2004.

[12] I. Okayasu, M. Fujitaka, Y. Hara, Y. Tanaka, and N. R. Rose, “Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma. A study of surgical cases among Japanese, and white and African Americans,” *Cancer*, vol. 76, no. 11, pp. 2312–2318, 1995.

[13] Y. Kataoka, H. Yotsuyanagi, K. Hashizume et al., “Pancreatic involvement in chronic viral hepatitis,” *World Journal of Gastroenterology*, vol. 11, no. 23, pp. 3508–3513, 2005.

[14] D. Taranto, A. Carrato, M. Romano, G. Maio, C. M. Izzo, and C. Del Vecchio Blanco, “Mild pancreatic damage in acute viral hepatitis,” *Digestion*, vol. 42, no. 2, pp. 93–97, 1989.

[15] S. Raza, N. A. Chaudhry, J. D. Brown et al., “To study the clinical, biochemical and radiological features of acute pancreatitis in HIV and AIDS,” *Journal of Clinical Medicine Research*, vol. 5, no. 1, pp. 12–17, 2013.

[16] S. C. Gumber and S. Chopra, “Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations,” *Annals of Internal Medicine*, vol. 123, no. 8, pp. 615–620, 1995.

[17] S. Silverman Jr, “Oral lichen planus: a potentially premalignant lesion,” *Journal of Oral and Maxillofacial Surgery*, vol. 58, no. 11, pp. 1286–1288, 2000.

[18] M. Malaguarnera, G. Pistone, S. Neri, M. Romano, A. Brogna, and S. Musumeci, “Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment,” *BioDrugs*, vol. 18, no. 6, pp. 407–413, 2004.

[19] M. Malaguarnera, N. Guccione, S. Musumeci, A. Brogna, M. Motta, and L. Di Fazio, “Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C,” *BioDrugs*, vol. 18, no. 1, pp. 63–70, 2004.

[20] M. Battegay, “Immunity to hepatitis C virus: a further piece of the puzzle,” *Hepatology*, vol. 24, no. 4, pp. 961–963, 1996.

[21] L. Malaguarnera, L. Ferlito, S. Di Mauro, R. M. Imbesi, G. Scalii, and M. Malaguarnera, “Immunosenescence and cancer: a review,” *Archives of Gerontology and Geriatrics*, vol. 32, no. 2, pp. 77–93, 2001.

[22] S. M. Woo, J. Joo, W. J. Lee et al., “Risk of pancreatic cancer in relation to ABO blood group and hepatitis C virus infection in Korea: a case-control study,” *Journal of Korean Medical Science*, vol. 28, no. 2, pp. 247–251, 2013.

[23] M. C. Chang, C. H. Chen, J. D. Liang et al., “Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma,” *World Journal of Gastroenterology*, vol. 20, no. 17, pp. 5060–5065, 2014.

[24] M. M. Hassan, D. Li, A. S. El-Deeb et al., “Association between hepatitis B virus and pancreatic cancer,” *Journal of Clinical Oncology*, vol. 26, no. 28, pp. 4557–4562, 2008.

[25] S. K. Abe, M. Inoue, N. Sawada et al., “Hepatitis B and C virus infection and risk of pancreatic cancer: a population-based cohort study (JPHC study cohort II),” *Cancer Epidemiology, Biomarkers & Prevention*, vol. 25, no. 3, pp. 555–557, 2016.

[26] J. Huang, M. Magnusson, A. Törner, W. Ye, and A. S. Duberg, “Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: a nationwide study in Sweden,” *British Journal of Cancer*, vol. 109, no. 11, pp. 2917–2923, 2013.
[27] H. B. El-Serag, E. A. Engels, O. Landgren et al., "Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of US veterans," *Hepatology*, vol. 49, no. 1, pp. 116–123, 2009.

[28] J. Amin, G. J. Dore, D. L. O’Connell et al., "Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study," *Journal of Hepatology*, vol. 45, no. 2, pp. 197–203, 2006.

[29] A. Antonelli, C. Ferri, P. Fallahi et al., "Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study," *Thyroid*, vol. 17, no. 5, pp. 447–451, 2007.

[30] M. Montella, L. Pezzullo, A. Crispo et al., "Risk of thyroid cancer and high prevalence of hepatitis C virus," *Oncology Reports*, vol. 10, no. 1, pp. 133–136, 2003.

[31] A. Antonelli, C. Ferri, P. Fallahi, C. Nesti, A. L. Zignego, and M. Maccheroni, "Thyroid cancer in HCV-related mixed cryoglobulinemia patients," *Clinical and Experimental Rheumatology*, vol. 20, no. 5, pp. 693–696, 2002.

[32] M. Montella, A. Crispo, G. de Bellis et al., "HCV and cancer: a case-control study in a high-endemic area," *Liver*, vol. 21, no. 5, pp. 335–341, 2001.

[33] A. Antonelli, C. Ferri, and P. Fallahi, "Thyroid cancer in patients with hepatitis C infection," *Journal of the American Medical Association*, vol. 281, no. 17, p. 1588, 1999.

[34] R. D. Allison, X. Tong, A. C. Moorman et al., "Chronic Hepatitis Cohort Study (CHeCS) investigators. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006–2010," *Journal of Hepatology*, vol. 63, no. 4, pp. 822–828, 2015.

[35] L. H. Omland, D. K. Farkas, P. Jepsen, N. Obel, and L. Pedersen, "Hepatitis C virus infection and risk of cancer: a population-based cohort study," *Clinical Epidemiology*, vol. 2, no. 2, pp. 179–186, 2010.

[36] A. Swart, L. Burns, L. Mao et al., "The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study," *BMJ Open*, vol. 2, no. 5, 2012.

[37] A. S. Duberg, M. Nordström, A. Törner et al., "Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection," *Hepatology*, vol. 41, no. 3, pp. 652–659, 2005.

[38] H. C. Gonzalez, L. Lamerato, C. G. Rogers, and S. C. Gordon, "Chronic hepatitis C infection as a risk factor for renal cell carcinoma," *Digestive Diseases and Sciences*, vol. 60, no. 6, pp. 1820–1824, 2015.

[39] M. Malaguarna, M. P. Gargante, C. Risino et al., "Hepatitis C virus in elderly cancer patients," *European Journal of Internal Medicine*, vol. 17, no. 5, pp. 325–329, 2006.

[40] B. Budakoglu, S. Aksoy, C. Arslan et al., "Frequency of HCV infection in renal cell carcinoma patients," *Medical Oncology*, vol. 29, no. 3, pp. 1892–1895, 2012.

[41] S. C. Gordon, D. Moonka, K. A. Brown et al., "Risk for renal cell carcinoma in chronic hepatitis C infection," *Cancer Epidemiology, Biomarkers & Prevention*, vol. 19, no. 4, pp. 1066–1073, 2010.

[42] J. N. Hofmann, A. Törner, W. H. Chow, W. Ye, M. P. Purdue, and A. S. Duberg, "Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden," *European Journal of Cancer Prevention*, vol. 20, no. 4, pp. 326–330, 2011.

[43] Y. Nagao, M. Sata, K. Itoh et al., "High prevalence of hepatitis C virus antibody and RNA in patients with head and neck squamous cell carcinoma," *Hepatology Research*, vol. 7, no. 3, pp. 206–212, 1997.

[44] Y. Takata, T. Takahashi, and J. Fukuda, "Prevalence of hepatitis virus infection in association with oral diseases requiring surgery," *Oral Diseases*, vol. 8, no. 2, pp. 95–99, 2002.

[45] F. H. Su, S. N. Chang, P. C. Chen et al., "Positive association between hepatitis C infection and oral cavity cancer: a nationwide population-based cohort study in Taiwan," *PloS One*, vol. 7, no. 10, article e48109, 2012.

[46] F. H. Su, S. N. Chang, P. C. Chen, F. C. Sung, C. T. Su, and C. C. Yeh, "Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study," *BMC Cancer*, vol. 11, no. 1, p. 495, 2011.

[47] D. Larrey, M. C. Bozonnat, I. Kain, G. P. Pageaux, and E. Assenat, "Is chronic hepatitis C virus infection a risk factor for breast cancer?" *World Journal of Gastroenterology*, vol. 16, no. 29, pp. 3687–3691, 2010.

[48] K. Uzun, S. Alci, B. Ozbay, M. Gencer, and H. Irmak, "The incidence of hepatitis C virus in patients with lung cancer," *The Turkish Respiratory Journal*, vol. 3, pp. 91–93, 2002.

[49] K. S. Zaret, "Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation," *Nature Reviews. Genetics*, vol. 9, no. 5, pp. 329–340, 2008.

[50] E. Wandzioch and K. S. Zaret, "Dynamic signaling network for the specification of embryonic pancreas and liver progenitors," *Science*, vol. 324, no. 5935, pp. 1707–1710, 2009.

[51] V. Wiwanitkit, "Renal cell carcinoma and hepatitis C virus infection: is there any cause-outcome relationship?" *Journal of Cancer Research and Therapeutics*, vol. 7, no. 2, pp. 226–227, 2011.
Submit your manuscripts at https://www.hindawi.com